Prevalence of vitamin D inadequacy in European postmenopausal women

被引：72

作者：

Bruyere, O. ^{[1
]}

Malaise, O.

Neuprez, A.

Collette, J.

Reginster, J.-Y.

机构：

[1] Univ Liege, CHU Sart Tilman, Dept Publ Hlth Epidemiol & Hlth Econ, B-4000 Liege, Belgium

[2] Univ Liege, CHU Sart Tilman, WHO, Collaborating Ctr Publ Hlth Aspect Osteoarticular, B-4000 Liege, Belgium

来源：

CURRENT MEDICAL RESEARCH AND OPINION | 2007年 / 23卷 / 08期

关键词：

osteoporosis; postmenopausal women; prevalence; vitamin D deficiency;

D O I：

10.1185/030079907X219562

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective: Inadequate vitamin D level is associated with secondary hyperparathyroidism and increased bone turnover and bone loss, which in turn increases fracture risk. The objective of this study is to assess the prevalence of inadequate serum vitamin D levels in postmenopausal European women. There are no clear international agreements on what constitutes a level of vitamin D inadequacy, but recent publications suggest that the circulating level of vitamin D should be over 80 nmol/L or at least between 50 and 80 nmol/L. Material and methods: Assessment of 25-hydroxyvitamin D [25(OH)D] was performed in 8532 European postmenopausal women with osteoporosis or osteopenia. European countries included France, Belgium, Denmark, Italy, Poland, Hungary, United Kingdom, Spain and Germany. Two cut-offs of 25(OH)D inadequacy were fixed < 80 nmol/L and < 50 nmol/L. Results: Mean (SD) age of the patients was 74.2 (7.1) years, body mass index was 25.7 (4.1)kg/m(2). Level of 25(OH)D was 61.0 (27.2) nmol/L. There was a highly significant difference of 25(OH)D level across European countries (p < 0.0001). The lowest level of 25(OH)D was found in France [51.5 (26.1) nmol/L] and the highest in Spain [85.2 (33.3) nmol/L]. In the whole study population, the prevalence of 25(OH)D inadequacy was 79.6% and 32.1 % when considering cut-offs of 80 and 50 nmol/L, respectively and when considering patients aged less than 65 years, the prevalence reached 86% (cut-off of 80 nmol/L) and 45% (cutoff of 50 nmol/L). Conclusion: This study indicates a high prevalence of vitamin D [25(OH)D] inadequacy in European postmenopausal women. The prevalence could be even higher in some particular countries. A greater awareness of the importance of vitamin D inadequacy is needed to address this public health problem.

引用

页码：1939 / 1944

页数：6

共 40 条

[11]

Boonen S., Body J.J., Boutsen Y., Et al., Evidence-based guidelines for the treatment of postmenopausal osteoporosis: A consensus document of the Belgian Bone Club, Osteoporosis Int, 16, pp. 239-254, (2005)

[12]

Compston J., Guidelines for the management of osteoporosis: The present and the future, Osteoporosis Int, 16, pp. 1173-1176, (2005)

[13]

Barragry J.M., France M.W., Corless D., Et al., Intestinal cholecalciferol absorption in the elderly and in younger adults, Clin Sci Mol Med, 55, pp. 213-220, (1978)

[14]

Reginster J.Y., The high prevalence of inadequate serum vitamin D levels and implications for bone health, Curr Med Res Opin, 21, pp. 579-586, (2005)

[15]

Hollis B.W., Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: Implications for establishing a new effective dietary intake recommendation for vitamin D, J Nutr, 135, pp. 317-322, (2005)

[16]

Gaugris S., Heaney R.P., Boonen S., Et al., Vitamin D inadequacy among post-menopausal women: A systematic review, QJM, 98, pp. 667-676, (2005)

[17]

Dawson-Hughes B., Heaney R.P., Holick M.F., Et al., Estimates of optimal vitamin D status, Osteoporosis Int, 16, pp. 713-716, (2005)

[18]

Heaney R.P., Vitamin D: How much do we need, and how much is too much?, Osteoporosis Int, 11, pp. 553-555, (2000)

[19]

Sidwell A.I., Wilkinson T.J., Hanger H.C., Secondary prevention of fractures in older people: Evaluation of a protocol for the investigation and treatment of osteoporosis, Int Med J, 34, pp. 129-132, (2004)

[20]

Holick M.F., Siris E.S., Binkley N., Et al., Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy, J Clin Endocrinol Metab, 90, pp. 3215-3224, (2005)

← 1 2 3 4 →